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The RNASEL gene on chromosome 1q25 was recently identified as a candidate gene for hereditary prostate cancer
(PC). To confirm these findings, we screened 326 patients from 163 families with familial PC for potential germline
mutations, by use of conformation-sensitive gel electrophoresis, followed by direct sequence analysis. A total of
six variants were identified, including one intronic and five exonic changes (three missense and two silent alterations).
There were no unequivocal pathogenic changes. To further test for potential associations between genes and
increased risk for disease, the three missense polymorphisms (Ile97Leu, Arg462Gln, andGlu541Asp)were genotyped
in 438 patients with familial PC and in 510 population-based control subjects. Association testing revealed no
significant differences between patients and control subjects for either the Leu97 variant (x2 trend test p 1.42;
) or the Asp541 variant ( ; ). However, significant differences were detected for the2Pp .23 x p 1.52 Pp .22
Arg462Gln genotypes ( ; ; odds ratio [OR] p 0.54; 95% confidence interval [CI] 0.32–0.91)2x p 5.20 Pp .02
when the genotype Gln/Gln was compared with Arg/Arg. In subset analyses, associations were also observed in
the younger group (age at diagnosis 64 years) ( ; ; 95% CIp 0.13–0.66), in node-negativePp .0008 ORp 0.29
patients ( 1; ; 95% CI 0.27–0.84), patients with stage T1/T2 disease ( ; ; 95%Pp .0 ORp 0.48 Pp .008 ORp 0.39
CI 0.2–0.75), and patients with low-grade disease ( ; ; 95% CI 0.20–0.78). To evaluate whetherPp .01 ORp 0.40
this variant was also associated with sporadic PC, we genotyped an additional 499 patients with sporadic PC.
Differences in frequency were not detected between patients with sporadic disease and control subjects. However,
the same association was observed between patients with familial disease and patients with sporadic disease for
the entire group ( ; ), as well as in the subset analyses. These results suggest that polymorphic2x p 4.82 Pp .03
changes within the RNASEL gene may be associated with increased risk of familial but not sporadic PC.
Introduction
It has been known for some time that prostate cancer
(PC) tends to cluster in some families (Cannon et al.
1982; Meikle and Stanish 1982; Steinberg et al. 1990;
Spitz et al. 1991; Carter et al. 1992; Goldgar et al. 1994;
Whittemore et al. 1995). Segregation analysis suggests
that this familial clustering can best be explained by at
least one rare dominant susceptibility gene (Carter et al.
1992; Schaid et al. 1998). However, evidence also points
to a complex genetic basis, involving multiple suscep-
tibility genes and variable phenotypic expression. On the
basis of linkage studies of families with high risk of PC,
six PC-susceptibility loci have been postulated to exist:
HPC1 (MIM 601518) localized to chromosome 1q24-
25 (Smith et al. 1996); PCAP (MIM 602759) to 1q42.2-
43 (Berthon et al. 1998); CAPB (MIM 603688) to 1p36
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(Gibbs et al. 1999); HPCX (MIM 300147) to Xq27-28
(Xu et al. 1998); HPC20 to 20q13 (Berry et al. 2000);
andHPC2 (MIM 605367) to17p (Tavtigian et al. 2001).
Among the six loci, two candidate genes have been pro-
posed:HPC2/ELAC2 on 17p (Tavtigian et al. 2001) and
RNASEL on 1q25 (Carpten et al. 2002). Variations of
the HPC2/ELAC2 were initially reported to be associ-
ated with PC risk (Rebbeck et al. 2000). However, recent
studies suggest that it likely plays a more limited role in
sporadic and hereditary PC (Rokman et al. 2001; Suarez
et al. 2001; Wang et al. 2001; Xu et al. 2001).
RNASEL (National Center for Biotechnology In-
formation nucleotide accession number NM_021133;
MIM 180435) was recently identified by a positional-
cloning/candidate method, and germline mutations
were reported to cosegregate within families with PC
linked to the HPC1 region, at 1q24-31 (Carpten et al.
2002). This gene has elsewhere been shown to play a
role in regulating cell proliferation and apoptosis
through the 2–5A pathway and has been suggested as
a candidate tumor-suppressor gene (Hassel et al. 1993;
Lengyel 1993).
To confirm whether alterations of RNASEL are as-
sociated with familial PC risk, we screened 326 patients
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with PC (two affected members per family) from 163
families that were defined as having familial PC (Berry
et al. 2000), for potential germline mutation. We also
examined the frequency of three polymorphisms
(Ile97Leu, Arg462Gln, and Glu541Asp) among 438 pa-
tients with familial PC, 499 patients with sporadic PC,
and 510 control subjects, for potential associationswith
the presence of PC.
Subjects and Methods
Patients with Familial PC
Ascertainment of families with PC has been described
elsewhere (Berry et al. 2000). In brief, on the basis of
surveys of 12,675 men performed at Mayo Clinic, ∼200
high-risk families were identified; families having a min-
imum of 3 men with PC were enrolled for further study.
Blood was collected from as many family members as
possible, resulting in a total of 473 affected men from
181 families. For 163 of these families, DNA informa-
tion was available on multiple living affected men. For
the remaining 18 families, DNA information was avail-
able on only a single affected individual. All men with
PC who contributed a blood specimen had their cancers
verified by review of medical records and pathologic
confirmation. One family has Hispanic ancestry; the re-
mainder consist of non-Hispanic white men.
In an effort to identify potential gene alterations that
segregate with disease, two affected members (the pro-
band and the youngest available affectedman) from each
of 163 families were selected for further analysis (total
326 patients). For the association study, all affected men
from the same generation (i.e., siblings and cousins)were
included. The decision to study men of the same gen-
eration was made to avoid large differences in ages and
to avoid secular trends based on year of diagnosis. Thus,
438 patients (consisting of singletons, siblings, and cous-
ins) were used for the association study. The research
protocol and informed consent forms were approved by
the Mayo Clinic institutional review board.
Patients with Sporadic PC
Patients with sporadic PC were selected from respon-
dents to our family history survey who reported no family
history of PC. To ensure that the sporadic group was
similar to the familial group, except for family history,
eligible patients with sporadic disease were selected by
frequency matching them to the familial index patients
(i.e., matched to have equal frequencies of categories,
rather than one-to-one matching), according to year of
diagnosis, age at diagnosis, and number of brothers.Mul-
tiple patients with sporadic disease were identified for
each familial case, and these case sets were randomly sam-
pled for recruitment, with a goal of recruiting ∼500 men
with sporadic PC. A total of 1,001 invitations were sent
to men who initially reported no family history of PC.
Our second survey determined that only 740 of these men
were eligible (i.e., still no family history of PC), and, of
these men, 501 agreed to contribute a blood sample. At
the timewhen assayswere performed, blood sampleswere
available for 499 men. All but 11 of these men were
treated surgically for their PC.
Population Controls for Association Study
From a sampling frame of the local population pro-
vided by the Rochester Epidemiology Project (Melton
1996), 475 men were randomly selected for a clinical
urologic examination (Oesterling et al. 1993). This ex-
amination included digital rectal examination (DRE)
and transrectal ultrasound (TRUS) of the prostate, ab-
dominal ultrasound for post void residual urine volume,
measurement of serum levels of prostate-specific antigen
(PSA) and creatinine, focused urologic physical exami-
nation, and cryopreservation of serum for subsequent
sex hormone assays. Any patient with an abnormal
DRE, elevated serum PSA level, or suspicious lesion on
TRUS was evaluated for prostatic malignancy. If the
DRE and TRUS were unremarkable but the serum PSA
level was elevated (14.0 ng/ml), then a sextant biopsy
(three cores from each side) of the prostate was per-
formed. An abnormal DRE or TRUS result, regardless
of the serum PSA level, prompted a biopsy of the area
in question. In addition, a sextant biopsy of the remaining
prostate was performed. Those men who were found to
be without PC on the basis of this extensive workup at
baseline or at any of the follow-up examinations through
1994 were used for the control population ( ).np 372
To make up for study attrition, the sample was aug-
mented with men who were randomly selected from the
population to undergo an identical workup ( ),np 138
resulting in a sample of 510 men without evidence of
PC (Roberts et al. 2000).
Conformation-Sensitive Gel Electrophoresis (CSGE) and
Direct Sequencing
The RNASEL gene has eight exons (Carpten et al.
2002). The sequences for the PCR primers covering the
coding sequence for six exons were kindly provided by
Dr. Carpten, of the National Human Genome Research
Institute, National Institutes of Health. CSGE has been
successfully used for mutation screening (Ganguly et al.
1993; Couch et al. 1996; Korkko et al. 1998). When
compared with sequencing, the CSGE detection rates in
our laboratory were 85%–100% (Park et al. 2000). Be-
cause the technique is dependent on formation of het-
eroduplexes, we mixed two samples from different fam-
ilies to maximize this possibility and to allow for more
efficient screening. PCR was performed for 30 cycles,
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with initial denaturation at 94C for 12 min, followed
by 94C for 20 s, 58C for 30 s, and 72C for 1 min.
The reaction was processed in a total volume of 12.5 ml
that consisted of dATP, dGTP, and dTTP (200 mMeach);
50 mMof dCTP; and 0.1 ml of 33P-dCTP, 2mMofMgCl2,
50 ng of template DNA, 1# AmpliTaq Gold buffer II,
and 0.5 units of TaqAmpliGold DNA polymerase (Per-
kin-Elmer). The PCR product was then denatured at
96C for 5 min and was cooled to 65C during the course
of 30 min. The reannealed product (5 ml) was thenmixed
with 1 ml of loading dye (30% glycerol, 0.25% bromo-
phenol blue, and 0.25% xylene cyanol FF). This mixture
(0.5 ml) was loaded on the conformation-sensitive gel,
which consisted of 15% of acrylamide and 1,4-bis (ac-
rolyl) piperazine (ratio 19:1), 0.5# TTE buffer (44.4
mM Tris, 14.25 mM taurine, and 0.1 mM EDTA, pH
9.0), 15% of formamide, and 10% of ethylene glycol.
The gel was run at 30 W for 5 h. When altered bands
were detected, the patient samples were reamplified sep-
arately, and 200 ng of purified PCR product and 3.8
pmol of sequencing primer were mixed and sequenced
using an ABI 377 automated sequencer.
Genotyping by Pyrosequencing
Three polymorphisms (Ile97Leu, Arg462Gln, and
Glu541Asp) in the RNASEL gene were genotyped in
438 patients with familial PC, 499 patients with sporad-
ic PC, and 510 control subjects. The PCR primers and
pyrosequencing primers are as follows:
1. 97F/97R: biotin-5′-TCTGCTTCGTCATGGTGCT/
CACACTCATTGACATCTGCTCC-3′;
2. 97-pyrosequencing: 5′-CAATCGCTGCGAGGA-3′;
3. 462F/462R: biotin-5′-TGGAAGCGTGTTTGGA-
TGT/TGTGGTTGCAGATCCTGGT-3′;
4. 462-pyrosequencing: 5′-TAGATGACAGGACAT-
TT-3′;
5. 541F/541R: biotin-5′-GGCTGGTCCTCTATGTG-
GTA/GGTCCTTAGTTTCCTCATCTGG-3′;
6. 541-pyrosequencing: 5′-TCATTACTTTGAGCT-
TTC-3′.
The primer pair 97F/97R was used to amplify a 134-
bp region containing the Ile97Leu variant. The 462F/
462R pair covered a 145-bp region containing the
Arg462Gln variant. The 541F/541R pair produced a
108-bp fragment containing the Glu541Asp variant.
All PCR assays were performed in a 25-ml reaction
volume consisting of 1# AmpliGold buffer II, 2 mM
MgCl2, 100 mM of each dNTP, 10 pmol of each primer,
0.75 U of TaqAmpliGold DNA polymerase, and 30 ng
of template DNA. PCR was performed using a Tetrad
thermal cycler (MJ Research) under the following con-
ditions: initial denaturation at 94C for 12 min, fol-
lowed by 40 cycles at 94C for 20 s, 40 cycles at 58C
for 30 s, and 40 cycles at 72C for 30 s.
The PCR products were mixed with 25 ml of 2# bind-
ing-washing buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM
EDTA, and 0.1% Tween 20, pH 7.6) and 10 ml of Dyna-
beads (Dynal AS) and were incubated on a thermomixer
(Eppendorf) (1,200 rpm) at 65C for 15 min. To obtain
single-strand DNA for subsequent pyrosequencing, Dy-
nabead-immobilized PCR products were denatured in
50 ml of 0.5 M NaOH for 1 min. Immobilized single
strands were transferred to 100 ml of 1# annealing buf-
fer (20 mM Tris acetate and 5 mM MgAc2, pH 7.6) for
1 min and were again transferred to 45 ml of 1# an-
nealing buffer containing 10 pmol of sequencing primer.
After denaturation at 95C for 3 min, the samples were
subjected to DNA sequencing in the PSQ96 system (Py-
rosequencing). The genotype of each sample was called
automatically by the instrument but was also evaluated
manually for potential misclassification.
Statistical Analysis
The association of each of the three polymorphisms
(Ile97Leu, Arg462Gln, and Glu541Asp) with familial
PC was evaluated by two statistical approaches. The first
approach compared genotype frequencies among pa-
tients with frequencies among control subjects, using a
test for trend in the number of variant alleles that is
analogous to the Armitage test for trend in proportions
(Sasieni 1997). For the unrelated patients with sporadic
disease, the trend test is exactly the Armitage test for
trend. For related patients with familial disease, a
method that accounts for the correlated family data by
correctly computing the variance of the trend test and
the variance of the odds ratios (ORs) was used, as de-
scribed elsewhere (Slager and Schaid 2001).
The second approach was based on unconditional lo-
gistic regression, to evaluate the main effects of the var-
iants between each group (patients with familial disease,
patients with sporadic disease, and control subjects)
while adjusting for age, which is a potential confounding
factor. For these analyses, age was defined as age at
diagnosis for patients and age at blood draw for control
subjects. In addition, age was categorized using quartiles
of the combined distribution of patients and control sub-
jects (quartiles were 42–56 years, 57–64 years, 65–69
years, and 70–84 years) or as a continuous variable. To
account for genotype correlations among patients from
the same family, generalized estimating equations were
used (Zeger and Liang 1986), assuming an exchangeable
working correlation matrix. All reported P values are
two sided.
Results
In an effort to identify gene alterations that segregate
with disease in our patients with familial disease, two
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Table 1
Analysis of RNASEL Gene in Patients
with Familial PC
Variant
Nucleotide
Change
Amino Acid
Change
Exons:
2 A289C Ile97Leu
2 C354T None
2 G1385A Arg462Gln
4 G1623T Glu541Asp
7 A2173G None
Intron IVS512 TrC None
affected members from each of 163 families were se-
lected for further analysis. Two individuals per family
were chosen to take into account the presence of phe-
nocopies, which are presumed to occur frequently in
families with hereditary PC.
Among the 326 patients with familial PC who were
screened for potential germline mutations, a total of six
variants (one intronic and five exonic) were identified
and confirmed by DNA sequencing (table 1). Of the five
exonic changes, two were common polymorphisms
(G1385A and G1623T), whereas the remaining three
were rare variants (A289C, A2173G, and C354T). The
GrA transition at base pair position 1385 causes an
amino acid change from arginine to glutamine at codon
462 (Arg462Gln). The allele frequencies for Arg and
Gln are ∼63% and 37%, respectively. The GrT trans-
version at base pair position 1623 results in a substi-
tution of glutamic acid for aspartic acid at codon 541
(Glu541Asp). The allele frequencies for Glu and Asp
are ∼57% and 43%, respectively. The ArC transversion
at base pair position 289 causes a replacement of iso-
leucine for leucine at codon 97 (Ile97Leu). The allele
frequencies for Ile and Leu are ∼99% and 1%, respec-
tively. The variants C354T and A2173G are silent. One
rare intronic change (TrC) was found in intron 5, 12
nt upstream from exon 5.
The three common missense variants (Ile97Leu,
Arg462Gln, and Glu541Asp) were genotyped in 438
patients with familial disease, 499 patients with spo-
radic disease, and 510 population control subjects to
evaluate whether the variant alleles at these loci were
associated with an increased risk of PC. Table 2 shows
the characteristics of the two PC patient groups and the
control group used in this analysis. The age range of
all three groups at diagnosis (patients) or at blood draw
(control subjects) was ∼45–85 years. However, the me-
dian age of the control group (55 years) was ∼10 years
less than that of the familial (66 years) or sporadic (65
years) groups, because a relatively large part of the con-
trol sample was !56 years old. Because of this differ-
ence, age was included in additional logistic regression
models, to statistically adjust for its potentially con-
founding effects.
Virtually all of the control subjects had a serum PSA
level !4 ng/ml, whereas the distribution of PSA values
was similar among familial and patients with sporadic
disease. Slightly less than half of the patients with fa-
milial disease underwent surgery, compared with 98%
of the patients with sporadic disease. This difference is
likely caused by the method of selection. Probands
(from the patients with familial disease) and the patients
with sporadic disease were selected primarily from a
radical prostatectomy database. The affected relatives
of the probands, on the other hand, were not selected
on the basis of treatment and therefore represent all
possible treatments. Because the sporadic-cancer group
is made up almost entirely of men treated with surgery,
there are fewer older men in this group. The lower part
of table 2 shows that the pathologic variables in the
surgical subsets of both groups are similar with respect
to nodal status, stage, and grade.
We first tested for potential associations of the various
genotypes with risk of familial PC. No significant asso-
ciations between patients and control subjectswere found
for either the Leu97 variant ( ) or the Asp541Pp .23
variant ( ; ). Analysis of theArg462Gln2x p 1.52 Pp .22
variant, on the other hand, showed a significant asso-
ciation between patients with familial disease and con-
trol subjects ( ) (table 3). In subset analyses, thePp .02
strongest association was seen in the younger patients
(age64 years), among whom we observed a significant
inverse association of the less common allele for both
homozygotes ( ; 95% CI 0.13–0.66) and het-ORp 0.29
erozygotes ( p0.63; 95%CI 0.41–0.95). We also sawOR
significant associations for node negative patients (Pp
), early stage (T1/T2; ), and low grade (6;.01 Pp .008
). However, in each of these subgroups, only thePp .01
ORs for the homozygotes reached statistical significance,
all showing an inverse association with the less common
allele. The ORs for the heterozygotes also indicated an
inverse association, but the 95% CIs overlapped 1.0 (ta-
ble 3). Similar results were obtained after adjusting for
age (data not shown). In addition to using age quartiles
to adjust for the effect of age (see “Subjects andMethods”
section), we investigated age as a continuous variable in
our regression models, to have more-refined adjustments
for age. The results obtained were very similar to the
results reported in table 3, further indicating that the
imbalance of age is not a major source of bias.
To evaluate whether the Arg462Gln variant is also
associated with sporadic PC, we genotyped this allele
in 499 patients with sporadic PC. No differences were
observed between patients with sporadic disease and
control subjects ( ; data not shown). However,Pp .92
we did detect a significant difference between patients
with sporadic versus those with familial disease ( 2x p
; ) (table 4), and this difference remained4.82 Pp .03
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Table 2
Characteristics of Patients with PC and Population-Based Control Subjects
Characteristica
Familial PC
(N p 438)b
Sporadic PC
(N p 499)b
Control
(N p 510)b Pc
Median age and range (years) 66 (45–84) 65 (46–79) 55 (42–83) …
Age quartiles (years): … … … …
42–56 37 (8.4) 53 (10.6) 273 (53.5) .001
57–64 133 (30.4) 182 (36.5) 98 (19.2) …
65–69 137 (31.3) 177 (35.5) 49 (9.6) …
70–84 131 (29.9) 87 (17.4) 90 (17.7) …
PSA: … … … …
!4 41 (12.2) 92 (22.7) 488 (95.7) .001
4–9.9 155 (46.1) 179 (44.2) 22 (4.3) …
10–19.9 68 (20.2) 73 (18.0) 0 (.0) …
20 72 (21.4) 61 (15.1) 0 (.0) …
Unknown 102 94 0 …
Surgical status: … … … …
No surgery 232 (53.0) 11 (2.2) … …
Surgical patient 206 (47.0) 488 (97.8) … …
Pathologic characteristics of all patients: … … … …
Nodal status: … … … …
Negative 379 (87.9) 413 (87.7) … .91
Positived 52 (12.1) 58 (12.3) … …
Unknown 7 28 … …
Stage:e … … … …
T1/T2 272 (71.8) 261 (64.0) … .02
T3/T4 107 (28.2) 147 (36.0) … …
Unknown 7 33 … …
Grade: … … … …
!7 251 (57.3) 268 (53.7) … .48
7 109 (24.9) 129 (25.9) … …
Unknown 78 (17.8) 102 (20.4)
Pathologic characteristics of surgical patients: … … … …
Nodal status: … … … …
Negative 181 (87.9) 411 (89.0) … .68
Positived 25 (12.1) 51 (11.0) … …
Unknown 0 26 … …
Stage:c … … … …
T1/T2 117 (64.6) 261 (64.0) … .88
T3/T4 64 (35.4) 147 (36.0) … …
Unknown 0 3 … …
Grade: … … … …
!7 112 (54.4) 267 (54.7) … .66
7 60 (29.1) 129 (26.4) … …
Unknown 34 (16.5) 92 (18.9)
a Age is defined as age at diagnosis for patients with familial or sporadic PC and as age at the time
of blood draw for control subjects.
b Data are no. (%), except as otherwise noted.
c Results from Pearson x2 test or Mantel-Haenszel test for trend.
d Includes patients who had metastatic disease.
e Patients whose nodal status was positive are excluded.
significant even after adjustment for age (heterozygous
; 95% CI 0.69–0.97). Moreover, the signif-ORp 0.82
icant associations from the subgroup analyses between
patients with familial disease and patients with sporadic
disease were of similar magnitude and in the same di-
rection as those between patients with familial disease
and control subjects. In almost all pathologically defined
subgroups, the associations were inverse, with the ho-
mozygous ORs for the younger, early-stage, node-neg-
ative, and lower-grade subgroups reaching statistical
significance (table 4).
Discussion
In the present study, gene analysis identified six var-
iants (none of which were pathogenic alterations) within
the RNASEL gene among our 326 patients with familial
PC. Carpten et al. (2002) reported a nonsense variant,
L. Wang et al.: RNASEL in Hereditary Prostate Cancer 121
Table 3
Association between PC and the RNASEL Arg462Gln Polymorphism: Familial vs. Controls
SUBJECT
CHARACTERISTIC N
NO. (%) OF SUBJECTS WITH
x2a P
OR (95% CI)
Arg/Arg Arg/Gln Gln/Gln Gln/Gln VS. Arg/Arg Arg/Gln VS. Arg/Arg
Control: 493 193 (39.2) 233 (47.3) 67 (13.6) … … … …
Age 64 years 357 141 (39.5) 164 (45.9) 52 (14.6) … … … …
Age 164 years 136 52 (38.2) 69 (50.7) 15 (11.0) … … … …
Familial: 433 198 (45.7) 198 (45.7) 37 (8.6) 5.20 .02 .54 (.32–.91) .83 (.61–1.13)
Age 64 years 169 92 (54.4) 67 (39.6) 10 (5.9) 11.28 .0008 .29 (.13–.66) .63 (.41–.95)
Age 164 years 264 106 (40.2) 131 (49.6) 27 (10.2) .13 .71 .88 (.41–1.91) .93 (.58–1.49)
Node negative 375 175 (46.7) 171 (45.6) 29 (7.7) 6.46 .01 .48 (.27–.84) .81 (.59–1.11)
Node positive 52 18 (34.6) 26 (50.0) 8 (15.4) .40 .53 1.28 (.53–3.11) 1.20 (.64–2.26)
Stage T1/T2 268 126 (47.0) 125 (46.6) 17 (6.3) 7.00 .008 .39 (.20–.75) .82 (.58–1.16)
Stage T3/T4 107 49 (45.8) 46 (43.0) 12 (11.2) 1.35 .24 .71 (.34–1.47) .78 (.49–1.24)
Low grade (6) 248 116 (46.8) 116 (46.8) 16 (6.5) 6.35 .01 .40 (.20–.78) .83 (.58–1.18)
High grade (17) 109 46 (42.2) 50 (45.9) 13 (11.9) .37 .54 .81 (.39–1.68) .90 (.56–1.44)
a Armitage test for trend on allele counts, accounting for related subjects.
Table 4
Association between PC and the RNASEL Arg462Gln Polymorphism: Patients with Familial PC
vs. those with Sporadic PC
PATIENT
CHARACTERISTIC N
NO. (%) OF PATIENTS WITH
x2a P
OR (95% CI)
Arg/Arg Arg/Gln Gln/Gln Gln/Gln VS. Arg/Arg Gln/Arg VS. Arg/Arg
Sporadic PC: 485 191 (39.4) 229 (47.2) 65 (13.4) … … … …
Age 64 years 228 94 (41.2) 108 (47.4) 26 (11.4) … … … …
Age 164 years 257 97 (37.7) 121 (47.1) 39 (15.2) … … … …
Node negative 402 163 (40.6) 184 (45.8) 55 (13.7) … … … …
Node positive 56 19 (33.9) 28 (50.0) 9 (16.1) … … … …
Stage T1/T2 254 112 (44.1) 106 (41.7) 36 (14.2) … … … …
Stage T3/T4 143 50 (35.0) 75 (52.5) 18 (12.6) … … … …
Low grade (6) 259 106 (40.9) 123 (47.5) 30 (11.6) … … … …
High grade (17) 125 45 (36.0) 63 (50.4) 17 (13.6) … … … …
Familial PC: 433 198 (45.7) 198 (45.7) 37 (8.6) 4.82 .03 .55 (.33–.93) .83 (.61–1.14)
Age 64 years 169 92 (54.4) 67 (39.6) 10 (5.9) 6.76 .009 .39 (.17–.93) .63 (.40–.99)
Age 164 years 264 106 (40.2) 131 (49.6) 27 (10.2) 1.25 .26 .63 (.34–1.20) .99 (.66–1.48)
Node negative 375 175 (46.7) 171 (45.6) 29 (7.7) 4.91 .03 .49 (.28–.87) .87 (.62–1.20)
Node positive 52 18 (34.6) 26 (50.0) 8 (15.4) .01 .92 .94 (.30–2.99) .98 (.42–2.27)
Stage T1/T2 268 126 (47.0) 125 (46.6) 17 (6.3) 2.84 .09 .42 (.21–.85) 1.05 (.71–1.55)
Stage T3/T4 107 49 (45.8) 46 (43.0) 12 (11.2) 1.88 .17 .68 (.29–1.62) .63 (.36–1.09)
Low grade (6) 248 116 (46.8) 116 (46.8) 16 (6.5) 3.04 .08 .49 (.23–1.02) .86 (.58–1.28)
High grade (17) 109 46 (42.2) 50 (45.9) 13 (11.9) .72 .40 .75 (.31–1.79) .78 (.44–1.38)
a Armitage test for trend on allele counts, accounting for related subjects.
E265X, which cosegregated in one of the HPC1-linked
families. In patients with this alteration, nuclease activity
in lymphoblasts was reported to be about half of that
seen in noncarriers of the mutation, suggesting that this
alteration results in a complete loss of protein. However,
the significance of the variant is questionable, since it
was also present in 3 of 330 men without PC and in 2
of 258 patients with sporadic PC (Carpten et al. 2002).
This mutation was not detected in any of our 326 fa-
milial PC patients. Although unequivocal pathogenic
mutations were not detected, we cannot exclude the pos-
sibility that some might have been missed because of the
location of the mutation (e.g., in the promoter region)
or because of technical limitations of the CSGE screening
method.
In addition to examining the RNASEL gene for the
presence of specific mutations, we also studied three
missense polymorphisms for their association with PC
risk. Of the three polymorphisms, only the Arg462Gln
variant showed an association with familial PC (Pp
), with OR p 0.54 and 0.83 for homozygous and.02
heterozygous carriers of the Gln462 variant, respec-
tively. Furthermore, when subsets of the patients with
familial PC were examined, this association was ob-
served with early age at diagnosis (64 years), node-
negative status, early-stage (T1/T2) disease, and low-
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grade (6) disease (table 3). Although the Arg462Gln
polymorphism exhibited a strong association with fa-
milial PC, no such association was observed with spo-
radic PC. However, significant differences were detected
between patients with sporadic versus those with fa-
milial disease, including the subgroup analyses (table
4). Overall, these data suggest a role for this poly-
morphism in familial, but not sporadic, PC. The re-
ported P values in the present study are nominal and
are not corrected for the statistical testing in multiple
subgroups. However, multiple testing will increase the
chance of a false-positive result only for the subgroup
analyses, not for our overall conclusion that this poly-
morphism may have a role in familial PC. Independent
replication of our findings will be important to support
our conclusions.
Interestingly, the increased risk of familial PC was
associated with the more common allele (Arg) of the
Arg462Gln polymorphism. This polymorphism is lo-
cated in the protein kinase domain of the conserved
region of the RNASEL protein. The functional signifi-
cance of the substitution of the basic amino acid Arg
by the neutral amino acid Gln is unclear. Thus, the
mechanism by which the Arg462 variant is associated
with familial PC is also unclear. Given that Arg462 is
the more common (∼63%) allele in the population, it
may be that this gene is a common modifier of other
existing, but rare, susceptibility genes, explaining its ef-
fect in familial, but not sporadic, PC. Another possi-
bility is that the Gln462 variant is in linkage disequi-
librium with another undetected polymorphism within
the RNASEL gene or with another unidentified gene
nearby. Additional studies are needed to clarify the sig-
nificance of these findings.
The analysis by subtype also raises some interest-
ing questions. A consistent pattern is seen for the
Arg462Gln variant, with no association observed (ei-
ther direct or indirect) with advanced or aggressive tu-
mors but, rather, an inverse association with less ag-
gressive tumors and with tumors identified in younger
men. This suggests the possibility that the variant serves
as a marker for more indolent disease. However, since
this association is not seen among patients with sporadic
disease, additional factors must be present in the fa-
milial group. The finding of genetic abnormalities that
are associated with early-stage and apparently less ma-
lignant tumors has been reported in other malignancies.
For example, defective mismatch repair in colon cancer
is associated with early-stage disease and an overall im-
proved survival (Thibodeau et al. 1998; Halling et al.
1999). Since there appears to be a correlation between
the clinical features and this polymorphism, the ability
to detect the effect of this allele may be dependent upon
the clinical features within the study population (i.e.,
the proportion of patients with high versus low grade
and high versus low stage). Again, similar subtype anal-
yses should be investigated further in other populations
to confirm and extend these findings.
In summary, we failed to detect any pathogenic mu-
tations in the RNASEL gene in our 326 patients with
familial PC. However, association studies in 438 pa-
tients with familial PC, 499 patients with sporadic PC,
and 510 population-based control subjects showed that
variants within the gene do appear to influence the risk
of familial PC, with higher risks observed in subsets of
these familial PC patients. The finding of allelic asso-
ciations within the RNASEL gene supports its involve-
ment in familial PC. However, more studies are needed
to elucidate the mechanism responsible for this asso-
ciation in familial PC.
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